Fredag 4 Juli | 03:42:12 Europe / Stockholm

Bifogade filer

Prenumeration

Kalender

Est. tid*
2026-05-28 07:30 Bokslutskommuniké 2026
2026-03-05 07:30 Kvartalsrapport 2026-Q3
2025-11-26 07:30 Kvartalsrapport 2026-Q2
2025-09-05 N/A X-dag halvårsutdelning EKTA B 1.2
2025-09-04 N/A Årsstämma
2025-08-28 07:30 Kvartalsrapport 2026-Q1
2025-05-28 - Bokslutskommuniké 2025
2025-03-06 - X-dag halvårsutdelning EKTA B 1.2
2025-02-21 - Kvartalsrapport 2025-Q3
2024-11-27 - Kvartalsrapport 2025-Q2
2024-09-06 - X-dag halvårsutdelning EKTA B 1.2
2024-09-05 - Årsstämma
2024-08-28 - Kvartalsrapport 2025-Q1
2024-06-05 - Bokslutskommuniké 2024
2024-02-29 - Kvartalsrapport 2024-Q3
2024-02-26 - X-dag halvårsutdelning EKTA B 1.2
2023-11-30 - Kvartalsrapport 2024-Q2
2023-08-25 - X-dag halvårsutdelning EKTA B 1.2
2023-08-24 - Årsstämma
2023-08-24 - Kvartalsrapport 2024-Q1
2023-05-25 - Bokslutskommuniké 2023
2023-02-24 - X-dag halvårsutdelning EKTA B 1.2
2023-02-24 - Kvartalsrapport 2023-Q3
2022-11-24 - Kvartalsrapport 2023-Q2
2022-08-26 - X-dag halvårsutdelning EKTA B 1.2
2022-08-25 - Årsstämma
2022-08-25 - Kvartalsrapport 2023-Q1
2022-05-25 - Bokslutskommuniké 2022
2022-02-24 - X-dag halvårsutdelning EKTA B 1.1
2022-02-24 - Kvartalsrapport 2022-Q3
2021-11-25 - Kvartalsrapport 2022-Q2
2021-08-26 - X-dag halvårsutdelning EKTA B 1.1
2021-08-25 - Årsstämma
2021-08-25 - Kvartalsrapport 2022-Q1
2021-05-28 - Bokslutskommuniké 2021
2021-04-19 - X-dag bonusutdelning EKTA B 0.9
2021-04-16 - Extra Bolagsstämma 2021
2021-02-25 - Kvartalsrapport 2021-Q3
2020-11-26 - Kvartalsrapport 2021-Q2
2020-08-27 - X-dag halvårsutdelning EKTA B 0.9
2020-08-26 - Årsstämma
2020-08-26 - Kvartalsrapport 2021-Q1
2020-05-29 - Bokslutskommuniké 2020
2020-02-21 - X-dag halvårsutdelning EKTA B 0.9
2020-02-20 - Kvartalsrapport 2020-Q3
2019-11-28 - Kvartalsrapport 2020-Q2
2019-08-23 - X-dag halvårsutdelning EKTA B 0.9
2019-08-22 - Årsstämma
2019-08-22 - Kvartalsrapport 2020-Q1
2019-05-29 - Bokslutskommuniké 2019
2019-03-01 - X-dag halvårsutdelning EKTA B 0.7
2019-02-22 - Kvartalsrapport 2019-Q3
2018-11-29 - Kvartalsrapport 2019-Q2
2018-08-31 - X-dag halvårsutdelning EKTA B 0.7
2018-08-30 - Årsstämma
2018-08-30 - Kvartalsrapport 2019-Q1
2018-06-01 - Bokslutskommuniké 2018
2018-03-02 - Kvartalsrapport 2018-Q3
2018-02-22 - X-dag halvårsutdelning EKTA B 0.5
2017-11-30 - Kvartalsrapport 2018-Q2
2017-08-24 - X-dag halvårsutdelning EKTA B 0.5
2017-08-23 - Årsstämma
2017-08-23 - Kvartalsrapport 2018-Q1
2017-06-01 - Bokslutskommuniké 2017
2017-03-03 - X-dag halvårsutdelning EKTA B 0.25
2017-03-01 - Kvartalsrapport 2017-Q3
2016-12-01 - Kvartalsrapport 2017-Q2
2016-09-26 - Kapitalmarknadsdag 2016
2016-09-02 - X-dag halvårsutdelning EKTA B 0.25
2016-09-01 - Årsstämma
2016-09-01 - Kvartalsrapport 2017-Q1
2016-06-01 - Bokslutskommuniké 2016
2016-03-02 - Kvartalsrapport 2016-Q3
2015-12-03 - Kvartalsrapport 2016-Q2
2015-09-02 - X-dag ordinarie utdelning EKTA B 0.50 SEK
2015-09-01 - Årsstämma
2015-09-01 - Kvartalsrapport 2016-Q1
2015-06-02 - Bokslutskommuniké 2015
2015-03-04 - Kvartalsrapport 2015-Q3
2014-11-27 - Analytiker möte 2014
2014-11-27 - Kvartalsrapport 2015-Q2
2014-09-15 - Kapitalmarknadsdag 2014
2014-08-29 - X-dag bonusutdelning EKTA B 0.5
2014-08-29 - X-dag ordinarie utdelning EKTA B 1.50 SEK
2014-08-28 - Analytiker möte 2015
2014-08-28 - Årsstämma
2014-08-28 - Kvartalsrapport 2015-Q1
2014-05-28 - Analytiker möte 2014
2014-05-28 - Bokslutskommuniké 2014
2014-02-27 - Kvartalsrapport 2014-Q3
2013-12-04 - Kvartalsrapport 2014-Q2
2013-09-23 - Kapitalmarknadsdag 2013
2013-09-04 - X-dag ordinarie utdelning EKTA B 1.50 SEK
2013-09-04 - X-dag bonusutdelning EKTA B 0.5
2013-09-03 - Årsstämma
2013-09-03 - Kvartalsrapport 2014-Q1
2013-06-05 - Analytiker möte 2013
2013-06-05 - Bokslutskommuniké 2013
2013-03-05 - Extra Bolagsstämma 2013
2013-03-05 - Kvartalsrapport 2013-Q3
2012-12-04 - Kvartalsrapport 2013-Q2
2012-10-29 - Kapitalmarknadsdag 2012
2012-09-12 - Split EKTA B 1:4
2012-09-05 - X-dag ordinarie utdelning EKTA B 5.00 SEK
2012-09-03 - Årsstämma
2012-09-03 - Kvartalsrapport 2013-Q1
2012-06-05 - Analytiker möte 2012
2012-06-05 - Bokslutskommuniké 2012
2012-04-02 - Extra Bolagsstämma 2012
2012-03-05 - Kvartalsrapport 2012-Q3
2011-12-02 - Kvartalsrapport 2012-Q2
2011-09-14 - X-dag ordinarie utdelning EKTA B 4.00 SEK
2011-09-13 - Årsstämma
2011-09-13 - Kvartalsrapport 2012-Q1
2011-06-09 - Bokslutskommuniké 2011
2011-03-08 - Kvartalsrapport 2011-Q3
2010-12-07 - Kvartalsrapport 2011-Q2
2010-09-22 - X-dag ordinarie utdelning EKTA B 3.00 SEK
2010-09-21 - Kvartalsrapport 2011-Q1
2010-06-09 - Bokslutskommuniké 2010
2010-03-10 - Kvartalsrapport 2009-Q3
2009-12-10 - Kvartalsrapport 2009-Q2
2009-09-16 - X-dag ordinarie utdelning EKTA B 2.00 SEK
2009-09-15 - Årsstämma
2009-09-15 - Kvartalsrapport 2009-Q1
2008-09-19 - X-dag ordinarie utdelning EKTA B 1.75 SEK
2007-09-26 - X-dag ordinarie utdelning EKTA B 1.00 SEK
2006-09-21 - X-dag ordinarie utdelning EKTA B 1.00 SEK
2005-10-17 - Split EKTA B 1:3
2005-09-22 - X-dag ordinarie utdelning EKTA B 6.60 SEK
2004-09-22 - X-dag ordinarie utdelning EKTA B 0.00 SEK
2003-09-23 - X-dag ordinarie utdelning EKTA B 0.00 SEK
2002-10-01 - X-dag ordinarie utdelning EKTA B 0.00 SEK
2001-09-28 - X-dag ordinarie utdelning EKTA B 0.00 SEK
2000-10-02 - X-dag ordinarie utdelning EKTA B 0.00 SEK
1999-09-23 - X-dag ordinarie utdelning EKTA B 0.00 SEK

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Elekta är verksamt inom medicinteknikbranschen och fokuserar på utveckling, tillverkning och distribution av medicinsk utrustning för cancerbehandling och neurokirurgi. Bolagets produkter inkluderar strålterapimaskiner och bilddiagnostiksystem. Bolaget har en global marknadsposition. Elekta grundades 1972 och har sitt huvudkontor i Stockholm.
2019-11-05 07:30:00

First care center in Italy offers patients the latest technology breakthrough in personalized cancer care

NEGRAR-VERONA, Italy, November 5, 2019 - Elekta (EKTA-B.ST) today announced that the IRCCS Ospedale Sacro Cuore-Don Calabria Cancer Care Center has treated its first patient using Elekta Unity, a transformative magnetic resonance radiation therapy (MR/RT) system that enables personalized precision radiation therapy.

"The real-time images that Elekta Unity provides enables unprecedented precision in delivering therapeutic radiation, particularly to anatomies that can be clearly seen on MR images, and those which change or move during the treatment course," said Prof. Filippo Alongi, Head of the Advanced Radiation Oncology department at Sacro Cuore-Don Calabria Cancer Care Center and Associate Professor at the University of Brescia. "We are proud to be the first cancer center in Italy and southern Europe to offer this breakthrough advance in precision radiation medicine to our patients."

On October 21, Sacro Cuore-Don Calabria Cancer Care Center completed the treatment of a 73-year-old male prostate cancer patient. Following a multidisciplinary evaluation, the patient was offered a choice of active surveillance, robotic prostatectomy or radical radiation therapy. He opted for treatment with radiation therapy because it was a non-invasive approach to therapy and requested the most advanced technology available. Considering the characteristics of the patient and his tumor, the care team suggested that he enroll in the prospective observational study and registry approved by Ethical committee and Veneto Region. This protocol allows prostate cancer patients to be treated with Stereotactic Body Radiation Therapy (SBRT) in five sessions using Elekta Unity. The care team also recommended the use of a hydrogel spacer to enlarge the distance between prostate and rectum to optimize adaptive plan procedures. The treatment was then delivered over five consecutive working days using daily plan adaptation to optimize tumor targeting, and the spacer was clearly visible at T2 images provided by MRI on-board during each fraction.

This is the first detailed case report of daily adaptive prostate SBRT with a hydrogel rectal spacer, clearly visible on the 1.5 Tesla (T) MR, monitored in real time during each session using the high-end MR-imaging capabilities of Elekta Unity. The treatment was feasible, easy and completed without interruption. 

"The integration of high quality 1.5 T MR images with a cutting-edge linear accelerator is transforming the treatment of many cancer types, including the prostate cancer," said Prof. Alongi. "With Elekta Unity we can assess and adapt treatment during radiation delivery, which was not feasible using conventional image-guided radiation therapy approaches."

Sacro Cuore-Don Calabria Cancer Care Center is conducting a one-year study designed to help define a model of optimal clinical implementation of Elekta Unity in the treatment of prostate cancer, pancreatic cancer, oligometastases and in patients previously treated with radiation therapy and are not candidates for re-irradiation with conventional radiotherapy. The study will include 230 patients and will provide insight into how to optimize personnel needs, organizational processes and timing of treatment for the use of Elekta Unity in these cancer indications. The study will also evaluate the potential effects of clinical implementation of Elekta Unity on the health system. 

"Sacro Cuore has been providing expert and compassionate care to patients in Negrar and the larger Verona area for nearly one hundred years," said Renato Leite, Elekta's Executive Vice President Region Europe. "With the addition of Elekta Unity, the Sacro Cuore-Don Calabria Cancer Care Center remains faithful to its founding principles while embracing cutting-edge technology that enables precision radiation medicine. We share the Center's commitment to caring for each patient as an individual and commend Prof. Alongi and his colleagues for making personalized radiation therapy with Elekta Unity available to cancer patients in Italy and southern Europe."

To learn more, visit elekta.com/Unity (https://www.elekta.com/Unity).

Elekta Unity is CE-marked and 510(k) cleared. Not available in all markets.

# # #

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Public Affairs
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: raven.canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com (http://www.elekta.com) or follow @Elekta (https://twitter.com/Elekta)on Twitter.